Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cetrelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cetrelimab (JNJ-63723283) is under development for the treatment of metastatic or surgically unresectable urothelial cancer, chronic hepatitis B, muscle-invasive bladder cancer (MIBC), metastatic castration-resistant prostate cancer (second line and third line) advanced cancers such as colorectal cancer, non-small-cell lung cancer (NSCLC), melanoma, renal cancer, bladder cancer, small-cell lung cancer (SCLC) gastric and esophageal cancer. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody and targets programmed cell death protein 1 (PD1). It is a new molecular entity (NME). It was also under development for relapsed and refractory multiple myeloma.
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of Cetrelimab’s drug-specific PTSR and LoA scores, buy the report here.